 Description of heparin effect measured in blood samples: Blood samples will be drawn from intravasal catheters preferably arterial, alternatively central venous to examine heparin effect anti-Xa activity, thrombin generation assay TGA and thrombelastography TEG and other haematological analyses including antithrombin concentrations. Whole blood will be drawn on two separate days from minimum day 2 to maximum day 30 dependent on the dialysis therapy of ICU stay immediately before and 4 hours after dalteparin administration in order to measure tough and peak effect of heparin. Dalteparin effect in ICU patients undergoing dialysis therapy will be measured one day with and one day without ongoing dialysis therapy in order to distinguish the effect of AKI from the effect of continuous renal replacement therapy CRRT. 